Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 3/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29169801 | 0.92 | USP2 (0.50) | LMNAUSP2MGAMDNM1ALDH1A1 | |
| SCHEMBL142856 | 0.85 | CYP2D6 (0.47) | LMNAUSP2MGAMDNM1ALDH1A1 | |
| SCHEMBL9623258 | 0.85 | CYP2D6 (0.47) | LMNAUSP2MGAMDNM1ALDH1A1 | |
| SCHEMBL2385585 | 0.85 | CYP2D6 (0.47) | LMNAUSP2MGAMDNM1ALDH1A1 | |
| SCHEMBL8636200 | 0.85 | CYP2D6 (0.47) | LMNAUSP2MGAMDNM1ALDH1A1 | |
| SCHEMBL5963213 | 0.85 | CYP2D6 (0.47) | LMNAUSP2MGAMDNM1ALDH1A1 | |
| SCHEMBL139954 | 0.85 | CYP2D6 (0.47) | LMNAUSP2MGAMDNM1ALDH1A1 | |
| SCHEMBL8630707 | 0.85 | CYP2D6 (0.52) | LMNAUSP2MGAMALDH1A1CNR1 | |
| SCHEMBL1890335 | 0.85 | CYP2D6 (0.47) | LMNAUSP2MGAMDNM1ALDH1A1 | |
| SCHEMBL29064944 | 0.85 | CYP2D6 (0.47) | LMNAUSP2MGAMDNM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4705454-A2 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | Stoke Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705455-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | Stoke Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260055409-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2025-09-23 | — | — | US | disclosed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2024229421-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024227085-A2 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-112263682-B | PCSK 9-targeting antisense oligomers and conjugates | 罗氏创新中心哥本哈根有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2024-03-14 | — | — | US | disclosed |
| US-5852182-A | Thiol-derivatized oligonucleosides | ISIS PHARMACEUTICALS INC. (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1998011123-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| US-5578718-A | Thiol-derivatized nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0728139-A1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0724447-A1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-07 | — | — | EP | disclosed |
| EP-0716604-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| EP-0724447-A4 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS INC (US) | 1996-01-22 | — | — | EP | disclosed |
| WO-1995006659-A1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
| WO-1995006474-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
| WO-1993007883-A1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | LMNA 199/4885USP2 3255/4885MGAM 2389/4885 |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | LMNA 294/4885USP2 3981/4885MGAM 3340/4885 |
| US-20260055409-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | CYFIP1, SYNGR2, CYFIP2 | LMNA 2018/4885USP2 2831/4885MGAM 3658/4885 |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | PCSK9, SCD5, PCSK7 | LMNA 572/4885USP2 4081/4885MGAM 2439/4885 |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | PCSK9, PCSK7, PCSK6 | LMNA 199/4885USP2 3255/4885MGAM 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.